Year All20222021202020192017 FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer January 4, 2022 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 21 - 21 of 21
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer January 4, 2022
